Breast cancer is one of the most-researched illnesses in the world. But some men suffering from the disease say they’re not able to benefit from new research and treatments.

Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...

This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...

As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal ...

Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ETCompany ParticipantsPascal Soriot - Chief ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

With a trio of biotechs hitting the Nasdaq on Friday, it was easy to miss a smaller-scale public debut from another ...

Pharmaceutical heavyweights like Bristol Myers Squibb, AstraZeneca, and Eli Lilly are betting big on radiopharmaceuticals, ...